BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
Enrolling by invitation · NCT07618624 · Registry updated 2026-06-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Enrolling by invitation | Phase 2 | 2026-06-01 | NCT07618624 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shenzhou Cell Engineering Co., Ltd. | 1 |
| Sun Yat-sen University | 606 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou | China | 6 |
| Affiliated Hospital of Guangdong Medical University | Zhanjiang | China | 14 |
| Cancer Hospital of Shantou University Medical College | Shantou | China | 9 |
| Guangzhou First People's Hospital | Guangzhou | China | 7 |
| Shenzhen Second People's Hospital | Shenzhen | China | 17 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 113 |
| The First People's Hospital of Foshan | Foshan | China | 10 |
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou | China | 17 |
| ZhuJiang Hospital of Southern Medical University | Guangzhou | China | 27 |